ClinicalTrials.gg
RecruitingNCT07463092Updated Jun 11, 2026

Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy

An interventional study of Creatine Monohydrate and Maltodextrin in Prostate Cancer and Sarcopenia, sponsored by University of Sao Paulo. Recruiting at 1 site in Brazil. Open to male participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by University of Sao Paulo · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
40 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 134 studies in Prostatic Neoplasms with a site in Brazil — 24 open to participants now, 54 under way, 31 of them phase 3. Prostatic Neoplasms · Brazil.

Planned enrollment
105th of 113
34 · median 670
Started
2026
with 7 others
No phase
18 of 134
3 open now
Primary completion
2028-12
later than 44 of 53 live
Registered
131st of 134
by date

Among the 134 studies in Prostatic Neoplasms with a site in Brazil, this one is the 105th largest by planned enrollment of the 113 interventional ones that give a count, is one of 8 that started in 2026, is one of 18 with no phase, reaches primary completion later than 44 of the 53 other live ones, and was the 131st registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

24 of the 134 studies in Prostatic Neoplasms with a site in Brazil are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 40 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Prostatic Neoplasms with a site in Brazil, or all of them as a file.
02

Study summary

This randomized, double-blind, placebo-controlled clinical trial will investigate the effects of creatine supplementation combined with a 12-week supervised resistance training program on muscle mass, muscle strength, physical performance (e.g., parameters of sarcopenia), and muscle density in men with prostate cancer undergoing androgen deprivation therapy (ADT). ADT often causes loss of lean mass, reduced muscle strength, functional impairment, and increased fat mass. Eligible male patients will be randomly assigned to receive either creatine monohydrate or a placebo (maltodextrin) in a double-blind manner, in addition to participating in the resistance exercise program. Assessments will be performed at baseline and after the 12-week intervention period and will include:

  • Muscle density and architecture assessed by ultrasound
  • Body composition (lean mass and fat mass)
  • Muscle strength
  • Physical performance (functional performance tests)
  • Inflammatory biomarkers
  • Vascular function parameters

The primary goal is to assess whether creatine supplementation combined with resistance training can safely improve muscle quality and quantity, strength, and physical function in these patients. If effective and safe, the intervention could help reduce muscle loss and improve quality of life in men undergoing ADT.

Read the detailed description

Men receiving androgen-deprivation therapy (ADT) for prostate cancer often experience significant loss of muscle mass, reduction in muscle strength, and increased fat mass. These changes can lead to sarcopenia, poorer physical function, and lower quality of life. Resistance training is known to improve muscle mass and strength in this population, but it is not clear whether adding creatine supplementation can further enhance these benefits. This study will investigate whether combining creatine monohydrate supplementation with a 12-week supervised resistance training program leads to greater improvements in muscle health compared to resistance training alone. Creatine is a nutritional supplement that may help increase muscle energy availability and support muscle growth and function, but its effects in men undergoing ADT have not been fully established. Participants will be randomly assigned to receive either creatine monohydrate or a placebo (maltodextrin) once daily throughout the 12-week resistance training program. All patients will follow the same structured resistance exercise protocol, supervised by trained professionals. The study will evaluate changes in muscle mass, muscle strength, physical performance, muscle density measured by ultrasound, inflammatory markers, vascular function, and other indicators of muscle health. The goal of this study is to determine whether creatine supplementation is a safe and effective strategy to improve muscle quality, physical function, and overall health for men receiving ADT. Findings from this trial may help guide future recommendations for exercise and nutritional support in this population.

03

Conditions studied

  • Prostate Cancer
  • Sarcopenia

Keywords

  • Prostate Cancer
  • Androgen Deprivation Therapy
  • Creatine
  • Resistance Training
  • Muscle Density
  • Sarcopenia
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men aged ≥ 40 years;
  • Patients with or cytologically confirmed localized prostate cancer;
  • Patients who have undergone surgical castration or pharmacological castration with gonadotropin-releasing hormone (GnRH/LHRH) agonists or antagonists for at least six months prior to the start of the intervention;
  • Patients receiving continuous or intermittent androgen deprivation therapy;
  • Patients with an (ECOG) performance status ≤ 2;
  • Not engaged in resistance training in the three months prior to the intervention;
  • Not using creatine supplementation in the three months prior to the intervention;
  • Willing to participate in a 12-week intervention consisting of resistance training performed three times per week and daily supplementation with creatine monohydrate or maltodextrin.

Exclusion criteria

Exclusion Criteria:

  • Patients with insulin-dependent diabetes mellitus;
  • Patients with dialysis-dependent renal failure;
  • Patients with severe chronic liver disease;
  • Estimated (eGFR) \< 30 mL/min/1.73 m²;
  • Any hormonal treatment outside that established by the medical team;
  • Patients planning to undergo chemotherapy within the next six months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Creatine Supplementation + Resistance Training

    Participants assigned to the experimental arm will complete a 12-week supervised, progressive resistance training program and receive 5 g/day of creatine monohydrate. Creatine supplementation will be administered daily throughout the intervention period.

    Dietary Supplement: Creatine Monohydrate · Behavioral: Resistance training

  • Active comparator
    Placebo (Maltodextrin) + Resistance Training

    Participants assigned to the control arm will complete a 12-week supervised, progressive resistance training program and receive 5 g/day of maltodextrin. Maltodextrin will be administered daily throughout the intervention period.

    Dietary Supplement: Maltodextrin · Behavioral: Resistance training

Interventions

  • Dietary supplementCreatine Monohydrate

    Participants will receive 5 g/day of creatine monohydrate throughout the 12-week supervised resistance training program.

  • Dietary supplementMaltodextrin

    Participants will receive 5 g/day of maltodextrin, matched in appearance and caloric content to creatine, throughout the 12-week supervised resistance training program.

  • BehavioralResistance training

    Participants will complete a 12-week supervised, progressive resistance training program designed to improve muscle strength and muscle mass. Training sessions will be conducted under professional supervision and will occur three times per week. The program will target major muscle groups of the upper and lower body using weight machines and free weights. All participants in both study arms will follow the same resistance training protocol.

    Also known as: Strength training, Supervised resistance training, Progressive resistance training

06

What researchers measure

Primary outcomes

  1. Muscle Density (Ultrasound-derived Echo Intensity and Thickness)

    Muscle density will be assessed using ultrasound-derived measurements, including muscle thickness and echo intensity of selected muscle groups. Higher muscle density reflects improved muscle quality.

    Time frame: Baseline and 12 weeks.

Secondary outcomes

  1. Muscle strength

    Muscle strength will be assessed using a handgrip dynamometer. The higher value of three attempts will be used.

    Time frame: Baseline and 12 weeks.

  2. Muscle mass

    Muscle mass will be assessed using Dual-energy X-ray absorptiometry (DXA).

    Time frame: Baseline and 12 weeks.

07

Study locations

1 of 1 sites recruiting
  • School of Physical Education and Sport - USP
    São Paulo, São Paulo 05508-030, Brazil
    Recruiting
    • Guilherme WP da Fonseca, PhD · Contactguilhermefonseca@usp.br · +55 11 3091 2137
    • Comitê de Ética em Pesquisa da EEFE-USP · Contactcep39@usp.br · +55 11 3091 3097
    • Guilherme WP da Fonseca, PhD · Principal investigator
08

References and documents

Publications

  • Yuan F, Wang Y, Xiao X, Zhang X, Jing M, Kamecki H, Tan YG, Barreras SG, Aragon-Ching JB, Ma Z, Zhang P, Chang D, You Y. A systematic review evaluating the effectiveness of exercise training on physical condition in prostate cancer patients undergoing androgen deprivation therapy. Transl Androl Urol. 2023 Aug 31;12(8):1336-1350. doi: 10.21037/tau-23-272. Epub 2023 Aug 4. PubMed 37680229 ↗
  • McTiernan A, Friedenreich CM, Katzmarzyk PT, Powell KE, Macko R, Buchner D, Pescatello LS, Bloodgood B, Tennant B, Vaux-Bjerke A, George SM, Troiano RP, Piercy KL; 2018 PHYSICAL ACTIVITY GUIDELINES ADVISORY COMMITTEE*. Physical Activity in Cancer Prevention and Survival: A Systematic Review. Med Sci Sports Exerc. 2019 Jun;51(6):1252-1261. doi: 10.1249/MSS.0000000000001937. PubMed 31095082 ↗
  • Kovac MB, Pavlin T, Cavka L, Ribnikar D, Spazzapan S, Templeton AJ, Seruga B. The trajectory of sarcopenia following diagnosis of prostate cancer: A systematic review and meta-analysis. J Geriatr Oncol. 2023 Sep;14(7):101594. doi: 10.1016/j.jgo.2023.101594. Epub 2023 Jul 22. PubMed 37482497 ↗

Individual participant data

Plan to share: No — Decision has not been made yet

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2028, 31 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 31 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2026
First posted
Mar 10, 2026
StartActual
May 1, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Jan 2029
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07463092
Collaborators
InCor Heart Institute, Instituto do Cancer do Estado de São Paulo
Responsible party
Guilherme Wesley Peixoto da Fonseca (Professor, University of Sao Paulo) — Principal investigator
First posted
Mar 10, 2026
Start date
May 1, 2026
Primary completion
Dec 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Jun 11, 2026

Study contacts

Guilherme WP da Fonseca, PhD
Contact
guilhermefonseca@usp.br
+55 11 3091 2137
Comitê de Ética em Pesquisa da EEFE-USP
Contact
cep39@usp.br
+55 11 3091 3097
Guilherme WP da Fonseca, PhD
principal investigator · School of Physical Education and Sport - USP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Creatine monohydrate

Start the discussion